Neuroprotective action of halogenated derivatives of L-Phenylalanine

The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamate...

Full description

Saved in:
Bibliographic Details
Published in:Stroke (1970) Vol. 35; no. 5; pp. 1192 - 1196
Main Authors: KAGIYAMA, Tomoko, GLUSHAKOV, Alexander V, SUMNERS, Colin, ROOSE, Brandy, DENNIS, Donn M, PHILLIPS, M. Ian, OZCAN, Mehmet S, SEUBERT, Christoph N, MARTYNYUK, Anatoly E
Format: Journal Article
Language:English
Published: Hagerstown, MD Lippincott Williams & Wilkins 01-05-2004
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors. We tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO). 3,5-diiodo-L-tyrosine (DIT) and 3,5-dibromo-L-tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC50s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6+/-14.1 micromol/L and 127.5+/-13.3 micromol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7+/-14.1% and 57.1+/-12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo. DBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia.
AbstractList BACKGROUND AND PURPOSEThe aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors.METHODSWe tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO).RESULTS3,5-diiodo-L-tyrosine (DIT) and 3,5-dibromo-L-tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC50s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6+/-14.1 micromol/L and 127.5+/-13.3 micromol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7+/-14.1% and 57.1+/-12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo.CONCLUSIONSDBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia.
Background and Purpose— The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors. Methods— We tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO). Results— 3,5-diiodo- l -tyrosine (DIT) and 3,5-dibromo- l -tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC 50 s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6±14.1 μmol/L and 127.5±13.3 μmol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7±14.1% and 57.1±12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo. Conclusions— DBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia.
The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of presynaptic and postsynaptic mechanisms. Therefore, we hypothesized that endogenous derivatives of L-Phe, which display potent antiglutamatergic activity, may safely and efficaciously protect the brain during conditions characterized by overactivation of glutamate receptors. We tested this hypothesis in vitro with a combination of patch-clamp and lactate dehydrogenase (LDH) analyses in rat cultured neurons exposed to simulated ischemia, and in vivo using a rat model of experimental stroke caused by transient middle cerebral artery occlusion (MCAO). 3,5-diiodo-L-tyrosine (DIT) and 3,5-dibromo-L-tyrosine (DBrT), endogenous halogenated derivatives of L-Phe, attenuated GST by similar mechanisms as L-Phe, but with greater potency. For example, the IC50s for DIT and DBrT to depress the frequency of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate receptor-mediated mEPSCs were 104.6+/-14.1 micromol/L and 127.5+/-13.3 micromol/L, respectively. Depression of GST by DIT and DBrT persisted during energy deprivation. Furthermore, DBrT significantly reduced LDH release in neuronal cultures exposed to oxygen glucose deprivation. In rats subjected to transient MCAO, DBrT decreased the brain infarct volume and neurological deficit score to 52.7+/-14.1% and 57.1+/-12.0% of control values, respectively. DBrT neither altered atrioventricular nodal and intraventricular conduction in isolated heart, nor heart rate and blood pressure in vivo. DBrT, an endogenous halogenated derivative of L-Phe, shows promise as a representative of a novel class of neuroprotective agents by exerting significant neuroprotection in both in vitro and in vivo models of brain ischemia.
Author SEUBERT, Christoph N
MARTYNYUK, Anatoly E
ROOSE, Brandy
KAGIYAMA, Tomoko
DENNIS, Donn M
PHILLIPS, M. Ian
GLUSHAKOV, Alexander V
SUMNERS, Colin
OZCAN, Mehmet S
Author_xml – sequence: 1
  givenname: Tomoko
  surname: KAGIYAMA
  fullname: KAGIYAMA, Tomoko
  organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States
– sequence: 2
  givenname: Alexander V
  surname: GLUSHAKOV
  fullname: GLUSHAKOV, Alexander V
  organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States
– sequence: 3
  givenname: Colin
  surname: SUMNERS
  fullname: SUMNERS, Colin
  organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States
– sequence: 4
  givenname: Brandy
  surname: ROOSE
  fullname: ROOSE, Brandy
  organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States
– sequence: 5
  givenname: Donn M
  surname: DENNIS
  fullname: DENNIS, Donn M
  organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States
– sequence: 6
  givenname: M. Ian
  surname: PHILLIPS
  fullname: PHILLIPS, M. Ian
  organization: Department of Physiology and Functional Genomics, University of Florida, Gainesville, Fla, United States
– sequence: 7
  givenname: Mehmet S
  surname: OZCAN
  fullname: OZCAN, Mehmet S
  organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States
– sequence: 8
  givenname: Christoph N
  surname: SEUBERT
  fullname: SEUBERT, Christoph N
  organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States
– sequence: 9
  givenname: Anatoly E
  surname: MARTYNYUK
  fullname: MARTYNYUK, Anatoly E
  organization: Department of Anesthesiology, University of Florida, Gainesville, Fla, United States
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15723999$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/15073406$$D View this record in MEDLINE/PubMed
BookMark eNpNkNtKw0AQhhep2IO-ggRB7xL3kM1mvZN6hKKi9XqZbiY2kiY1mxT69m5toM7NXMw3Mz_fmAyqukJCLhiNGEvYNWXRx_w9or4Yl4rziNGEJhFVR2TEJI_DOOHpgIwoFTrksdZDMnbu2_NcpPKEDJmkSsQ0GZG7F-yaet3ULdq22GAAvtVVUOfBEsr6CytoMQsybIoN7AC3G83CtyVW2xJKqIoKT8lxDqXDs75PyOfD_Xz6FM5eH5-nt7PQyli1oc2TzPIkXySCZwvLOc1SjcBFboGKFHgaA8-YYFZIBBAWMytzVLFQEjClYkKu9nd93p8OXWtWhbNY-hRYd84olkolU-3Bmz1om9q5BnOzbooVNFvDqNk5NJQZ79AcHJo_h8Z7mZDz_ku3WGF2WO2leeCyB8BZKPMGKlu4f5ziQmstfgGSG31R
CODEN SJCCA7
CitedBy_id crossref_primary_10_1113_expphysiol_2011_058578
crossref_primary_10_3390_antiox10081168
crossref_primary_10_1016_j_neuropharm_2014_01_044
crossref_primary_10_1007_s11306_019_1615_1
crossref_primary_10_1080_10715762_2019_1668560
crossref_primary_10_3390_metabo9100240
crossref_primary_10_1039_C5RA19934D
crossref_primary_10_3389_fmolb_2021_630291
crossref_primary_10_1039_C6MB00137H
crossref_primary_10_1038_jcbfm_2012_198
crossref_primary_10_1021_acs_jproteome_1c00406
crossref_primary_10_1080_08941930591004449
crossref_primary_10_1039_C5MB00470E
crossref_primary_10_1113_expphysiol_2009_047936
crossref_primary_10_1016_j_freeradbiomed_2013_08_166
crossref_primary_10_1124_mol_104_005983
crossref_primary_10_5853_jos_2018_03454
crossref_primary_10_1016_j_taap_2020_115140
crossref_primary_10_1002_jnr_24226
crossref_primary_10_1038_sj_cdd_4402189
crossref_primary_10_1039_c3mb70040b
crossref_primary_10_1002_jlcr_4057
crossref_primary_10_1016_S0254_6272_18_30906_3
crossref_primary_10_1016_j_arr_2022_101730
crossref_primary_10_1016_j_ymgme_2005_06_014
crossref_primary_10_3389_fnins_2021_701355
crossref_primary_10_1007_s11055_013_9832_y
crossref_primary_10_1515_revneuro_2021_0048
Cites_doi 10.1159/000049127
10.1161/str.24.1.8418534
10.1161/01.RES.63.1.97
10.1038/sj.mp.4000976
10.1152/physrev.1999.79.4.1431
10.1016/S0031-9384(00)00276-6
10.1161/str.20.1.2643202
10.1097/00004647-200005000-00003
10.1185/030079902125000660
10.1038/nn936
10.1172/JCI111695
10.1089/105072501300176363
10.1523/JNEUROSCI.22-04-01273.2002
10.1124/mol.51.5.733
10.1161/str.26.11.2187
10.1002/jnr.10569
10.3995/jstroke.8.1
10.1021/bi982401l
ContentType Journal Article
Copyright 2004 INIST-CNRS
Copyright_xml – notice: 2004 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1161/01.STR.0000125722.10606.07
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4628
EndPage 1196
ExternalDocumentID 10_1161_01_STR_0000125722_10606_07
15073406
15723999
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3C
.55
.GJ
.XZ
.Z2
01R
08R
0R~
123
1J1
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5RE
5VS
6PF
71W
77Y
7O~
A9M
AAAXR
AAGIX
AAHPQ
AAJCS
AAMOA
AAMTA
AAPBV
AAQKA
AAQQT
AARTV
AASOK
AAUGY
AAXQO
AAYEP
AAYJJ
ABASU
ABBUW
ABDIG
ABQRW
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFS
ACGOD
ACILI
ACWDW
ACWRI
ACXNZ
ADBBV
ADFPA
ADGGA
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFDTB
AFFNX
AFUWQ
AGINI
AHMBA
AHOMT
AHRYX
AHVBC
AIJEX
AJIOK
AJNWD
AJNYG
AKALU
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
AYCSE
BAWUL
BCGUY
BOYCO
BQLVK
BS7
C45
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HZ~
IKREB
IKYAY
IN~
IPNFZ
IQODW
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
M18
N4W
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB3
OCUKA
ODA
ODMTH
OGROG
OHYEH
OJAPA
OK1
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RHF
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
TWZ
V2I
VVN
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YCJ
YFH
YHZ
YQJ
YYP
ZA5
ZB8
ZGI
ZZMQN
AAAAV
AAIQE
AASCR
AAUEB
ABJNI
ABVCZ
ACLDA
ACXJB
ADHPY
AFEXH
AFSOK
AHQNM
AINUH
AJZMW
CGR
CUY
CVF
ECM
EIF
ERAAH
HLJTE
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c547t-cf6dc26fb632dbc220d89ea23fca038a284a2d131c35eaa3cedc5fe74375ae803
ISSN 0039-2499
IngestDate Sat Aug 17 00:05:05 EDT 2024
Fri Nov 22 01:07:07 EST 2024
Tue Oct 15 23:28:14 EDT 2024
Sun Oct 22 16:04:11 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Stroke
Nervous system diseases
Phenylalanine
Cardiovascular disease
Glutamate receptor
Glutamate
excitotuxicity
Cerebral disorder
Vascular disease
Aminoacid
neuroprotection
Central nervous system disease
receptors, glutamate
Antidepressant agent
Cerebrovascular disease
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c547t-cf6dc26fb632dbc220d89ea23fca038a284a2d131c35eaa3cedc5fe74375ae803
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1161/01.str.0000125722.10606.07
PMID 15073406
PQID 71857589
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_71857589
crossref_primary_10_1161_01_STR_0000125722_10606_07
pubmed_primary_15073406
pascalfrancis_primary_15723999
PublicationCentury 2000
PublicationDate 2004-05-01
PublicationDateYYYYMMDD 2004-05-01
PublicationDate_xml – month: 05
  year: 2004
  text: 2004-05-01
  day: 01
PublicationDecade 2000
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
PublicationTitle Stroke (1970)
PublicationTitleAlternate Stroke
PublicationYear 2004
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_19_2
e_1_3_2_1_2
e_1_3_2_10_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
e_1_3_2_14_2
References_xml – ident: e_1_3_2_4_2
  doi: 10.1159/000049127
– ident: e_1_3_2_14_2
  doi: 10.1161/str.24.1.8418534
– ident: e_1_3_2_15_2
– ident: e_1_3_2_11_2
  doi: 10.1161/01.RES.63.1.97
– ident: e_1_3_2_7_2
  doi: 10.1038/sj.mp.4000976
– ident: e_1_3_2_19_2
  doi: 10.1152/physrev.1999.79.4.1431
– ident: e_1_3_2_18_2
  doi: 10.1016/S0031-9384(00)00276-6
– ident: e_1_3_2_13_2
  doi: 10.1161/str.20.1.2643202
– ident: e_1_3_2_5_2
  doi: 10.1097/00004647-200005000-00003
– ident: e_1_3_2_6_2
  doi: 10.1185/030079902125000660
– ident: e_1_3_2_2_2
  doi: 10.1038/nn936
– ident: e_1_3_2_9_2
  doi: 10.1172/JCI111695
– ident: e_1_3_2_17_2
  doi: 10.1089/105072501300176363
– ident: e_1_3_2_3_2
  doi: 10.1523/JNEUROSCI.22-04-01273.2002
– ident: e_1_3_2_10_2
  doi: 10.1124/mol.51.5.733
– ident: e_1_3_2_1_2
  doi: 10.1161/str.26.11.2187
– ident: e_1_3_2_8_2
  doi: 10.1002/jnr.10569
– ident: e_1_3_2_12_2
  doi: 10.3995/jstroke.8.1
– ident: e_1_3_2_16_2
  doi: 10.1021/bi982401l
SSID ssj0002385
Score 1.9679595
Snippet The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission (GST) via a unique set of...
Background and Purpose— The aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission...
BACKGROUND AND PURPOSEThe aromatic amino acid L-Phenylalanine (L-Phe) significantly and reversibly depresses excitatory glutamatergic synaptic transmission...
SourceID proquest
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 1192
SubjectTerms Animals
Biological and medical sciences
Disease Models, Animal
In Vitro Techniques
Infarction, Middle Cerebral Artery - drug therapy
Infarction, Middle Cerebral Artery - prevention & control
L-Lactate Dehydrogenase - metabolism
Male
Medical sciences
Neurology
Neurons - enzymology
Neuroprotective Agents - pharmacology
Neuroprotective Agents - therapeutic use
Patch-Clamp Techniques
Phenylalanine - analogs & derivatives
Phenylalanine - pharmacology
Phenylalanine - therapeutic use
Rats
Rats, Sprague-Dawley
Receptors, Glutamate - drug effects
Receptors, Glutamate - physiology
Stroke - drug therapy
Stroke - metabolism
Stroke - pathology
Synaptic Transmission - drug effects
Synaptic Transmission - physiology
Tyrosine - analogs & derivatives
Tyrosine - pharmacology
Tyrosine - therapeutic use
Vascular diseases and vascular malformations of the nervous system
Title Neuroprotective action of halogenated derivatives of L-Phenylalanine
URI https://www.ncbi.nlm.nih.gov/pubmed/15073406
https://search.proquest.com/docview/71857589
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swEBdpC2Mwxr6XfXR-2KszWfKXHtsmobCsg8WFvglFH9tIY5cmLvS_30mWY6esbHvYi0kUywl3l7vfSaffIfRRMUYM4NRQSkPDGLLakGmNw0Rjhk2mdeJ4Ck7n2dlFPp7Ek8Gg3T3vxv6rpmEMdG1Pzv6DtrcPhQF4DTqHK2gdrn-ld8e24dkXbFWQ7wVuMaFdp9GlsBhTwU-5cZzfrpRjFtpSr9tLW-fYbrR7xDrfXFdLB0QjluHewsFn8f3nrVg58FlUq2pZbWt5Luv1D7GsbnZO0HTltPN6VfrWbCe2Z1C36ePbPB5DAPWkt-2CRNyV_420d6IkDu2Z176XbUhJvDUlPZcZRU0zPB9-4W36e9eeRu64wmhefHOskwDNMkJGkNM6AtYuoLWb-Gdf-fR8NuPF5KLYQwcEXBF4woOj6bg43kZrgCyJJ6OFb_h0__N3gMujK7GG_5Bpmp_cn504lFI8QY99ehEcNXbxFA10-Qw9-OILKJ6j8R3zCBrzCCoT9Mwj6JmH_eiOebxA59NJcXIa-kYaoUzibBNKkypJUrNIKVELSQhWOdOCUCMFprkAiCKIimgkaaKFoFIrW4QI4DJLhM4xfYn2y6rUr1FAtWQy1pFYLABIC5WnJk2xZpFRiRGMDhFtpcSvGr4U7vLMNOI44iBb3smWO9lynA3R4Y5Au6lwG0BoNkQfWglz8H92U0uUuqrXPLNkZkkOd7xqBN-bC-EL8OqbP859ix52hvwO7W-ua_0e7a1VfejN5Re5in8j
link.rule.ids 315,782,786,27933,27934
linkProvider Ovid
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuroprotective+action+of+halogenated+derivatives+of+L-phenylalanine&rft.jtitle=Stroke+%281970%29&rft.au=Kagiyama%2C+Tomoko&rft.au=Glushakov%2C+Alexander+V&rft.au=Sumners%2C+Colin&rft.au=Roose%2C+Brandy&rft.date=2004-05-01&rft.eissn=1524-4628&rft.volume=35&rft.issue=5&rft.spage=1192&rft.epage=1196&rft_id=info:doi/10.1161%2F01.STR.0000125722.10606.07&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-2499&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-2499&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-2499&client=summon